Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer.
Bando H, Yamada Y, Tanabe S, Nishikawa K, Gotoh M, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Bando H, et al. Among authors: yasui h. Gastric Cancer. 2016 Jul;19(3):919-26. doi: 10.1007/s10120-015-0549-1. Epub 2015 Oct 16. Gastric Cancer. 2016. PMID: 26474989 Clinical Trial.
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Iwasa S, Nagashima K, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Yasui H, Kato K, Okita NT, Shimada Y, Yamada Y. Iwasa S, et al. Among authors: yasui h. Cancer Chemother Pharmacol. 2015 Sep;76(3):605-14. doi: 10.1007/s00280-015-2834-4. Epub 2015 Jul 29. Cancer Chemother Pharmacol. 2015. PMID: 26220845 Clinical Trial.
Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.
Hamada C, Yamada Y, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hyodo I. Hamada C, et al. Among authors: yasui h. Int J Clin Oncol. 2016 Aug;21(4):668-675. doi: 10.1007/s10147-015-0938-9. Epub 2016 Jan 5. Int J Clin Oncol. 2016. PMID: 26733020 Review.
Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.
Nishikawa K, Yamada Y, Ishido K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Nishikawa K, et al. Among authors: yasui h. Gastric Cancer. 2017 Jul;20(4):640-645. doi: 10.1007/s10120-016-0666-5. Epub 2016 Nov 7. Gastric Cancer. 2017. PMID: 27822684 Clinical Trial.
1,326 results